Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
DTIL Precision Biosciences Inc
- Stocks
- Healthcare
- NASDAQ: DTIL
Price (delayed)
$5.1
Market cap
$56.55M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.58
Enterprise value
-$13.49M
Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its wholly proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome
Highlights
Precision Biosciences's quick ratio has surged by 79% YoY and by 11% QoQ
DTIL's EPS has soared by 66% year-on-year
The company's equity rose by 33% YoY but it fell by 13% QoQ
Precision Biosciences's gross profit has decreased by 26% from the previous quarter and by 11% YoY
Precision Biosciences's revenue has decreased by 26% from the previous quarter and by 11% YoY
Key stats
What are the main financial stats of DTIL
Market
Valuations
Earnings
Shares outstanding
11.09M
Market cap
$56.55M
Enterprise value
-$13.49M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.08
Price to sales (P/S)
0.93
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.26
Revenue
$51.14M
Gross profit
$51.14M
Operating income
-$44.09M
Net income
-$21.99M
EBIT
-$20.42M
EBITDA
-$16.57M
Free cash flow
-$58.74M
Per share
Balance sheet
Liquidity
EPS
-$2.58
EPS diluted
-$2.53
Free cash flow per share
-$6.32
Book value per share
$4.71
Revenue per share
$5.5
TBVPS
$13.32
Total assets
$124.41M
Total liabilities
$75.07M
Debt
$29.75M
Equity
$49.34M
Working capital
$69.71M
Debt to equity
0.6
Current ratio
6.62
Quick ratio
8.05
Net debt/EBITDA
4.23
Margins
Efficiency
Dividend
EBITDA margin
-32.4%
Gross margin
100%
Net margin
-43%
Operating margin
-86.2%
Return on assets
-15.2%
Return on equity
-35.9%
Return on invested capital
-54.2%
Return on capital employed
-18.2%
Return on sales
-39.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
DTIL stock price
How has the Precision Biosciences stock price performed over time
Intraday
-0.97%
1 week
2.62%
1 month
-11.3%
1 year
-61.45%
YTD
33.86%
QTD
6.92%
Financial performance
How have Precision Biosciences's revenue and profit performed over time
Revenue
$51.14M
Gross profit
$51.14M
Operating income
-$44.09M
Net income
-$21.99M
Gross margin
100%
Net margin
-43%
The operating margin has dropped by 126% since the previous quarter and by 43% year-on-year
DTIL's operating income has shrunk by 69% QoQ and by 28% YoY
Precision Biosciences's gross profit has decreased by 26% from the previous quarter and by 11% YoY
Precision Biosciences's revenue has decreased by 26% from the previous quarter and by 11% YoY
Price vs fundamentals
How does DTIL's price correlate with its fundamentals
Growth
What is Precision Biosciences's growth rate over time
Valuation
What is Precision Biosciences stock price valuation
P/E
N/A
P/B
1.08
P/S
0.93
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.26
DTIL's EPS has soared by 66% year-on-year
DTIL's P/B is 69% below its 5-year quarterly average of 3.5 but 21% above its last 4 quarters average of 0.9
The company's equity rose by 33% YoY but it fell by 13% QoQ
The P/S is 84% lower than the 5-year quarterly average of 5.7 but 34% higher than the last 4 quarters average of 0.7
Precision Biosciences's revenue has decreased by 26% from the previous quarter and by 11% YoY
Efficiency
How efficient is Precision Biosciences business performance
The return on invested capital has surged by 84% year-on-year
Precision Biosciences's return on equity has surged by 61% YoY
DTIL's ROS is up by 10% year-on-year
Precision Biosciences's ROA has increased by 5% YoY
Dividends
What is DTIL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for DTIL.
Financial health
How did Precision Biosciences financials performed over time
Precision Biosciences's total assets is 66% more than its total liabilities
Precision Biosciences's quick ratio has surged by 79% YoY and by 11% QoQ
The total liabilities is down by 49% year-on-year and by 6% since the previous quarter
DTIL's debt is 40% lower than its equity
The debt to equity has surged by 161% year-on-year and by 13% since the previous quarter
The company's equity rose by 33% YoY but it fell by 13% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.